In our cohort of MDS/MPN-SF3B1-T patients, bone marrow RS ≥ 15% was also considered a favorable prognostic factor for survival, whereas SF3B1 mutation was not confirmed to have prognostic significance. This evidence concerns the gene SF3B1 and myeloproliferative neoplasm.